botulinum antitoxin heptavalent (a b c d e f g) - (equine)
Biologicalexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2006 (NCT00360737)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Clostridium botulinum AImmunity, passive
Clostridium botulinum A immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- botulinum antitoxin heptavalent (a b c d e f g) - (equine)
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00360737 | Phase 1 | Jul 1, 2006 | Cangene, Department of Health and Human Services, MDS Pharma |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cangene | For profit | 1 | 1 | 1 | 2006 |
| Department of Health and Human Services | Government | 1 | 0 | 1 | 2006 |
| MDS Pharma | For profit | 1 | 0 | 1 | 2006 |
3 organizations
Page 1 / 1